Ilaria Rinaldi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ilaria Rinaldi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Angelo Schiavi
University of Rome Sapienza Rome Italy
2 shared publicationsAntoni Rucinski
Institute of Nuclear Physics PAN Krakow Poland
2 shared publications- Esther Decabooter
Department of Radiation Oncology (Maastro clinic), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands
2 shared publications Jan Gajewski
Institute of Nuclear Physics PAN Krakow Poland
2 shared publications- Mirko Unipan
Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+ , Maastricht, The Netherlands
2 shared publications Nils Krah
Holland Proton Therapy Centre Delft The Netherlands
2 shared publications
Latest Publications
- Open Access
Five Years of Clinical Application of independent Monte Carlo-Based Patient-Specific Quality Assurance at the Maastro Proton Therapy Center
At the Maastro Proton Therapy Center in Maastricht, patient-specific quality assurance (PSQA) using an independent GPU-accelerated Monte Carlo (MC) calculation has fully replaced conventional measurements, which are time-consuming and have limited sensitivity to clinically relevant errors. A fully automated and robust pipeline was developed, integrating two clinical workflows based on the fast MC code Fred. The system is fully operational, and automatic verification reports are part of daily clinical practice. The first workflow performs a pre-treatment dose recalculation in Fred using the planning CT and clinical plan. The second uses Fred with machine log files to verify the actually delivered dose. Both generate automatic reports for clinical review. Over five years, this workflow has become part of routine clinical operations, providing robust 3D dosimetric verification in heterogeneous anatomies. So far, Fred has recalculated more than 6000 pre-treatment plans and 3513 log file-based PSQA cases, saving an estimated 4090 hours of QA work. The pipeline identified true negatives and detected two planning-related failures that would have been missed by conventional measurements. No false positives or negatives were observed, confirming high accuracy and reliability. The MC-based PSQA pipeline offers an efficient, sensitive, and clinically meaningful alternative to measurement-based QA in pencil beam scanning proton therapy. By eliminating routine measurements, it saves resources while improving patient safety and treatment quality. Five years of experience confirm that measurement-less MC-based PSQA is a viable and superior approach, providing full 3D verification and early error detection - a practical blueprint for other proton therapy centres.
Open AccessFive Years of Clinical Application of independent Monte Carlo-Based Patient-Specific Quality Assurance at the Maastro Proton Therapy Center
At the Maastro Proton Therapy Center in Maastricht, patient-specific quality assurance (PSQA) using an independent GPU-accelerated Monte Carlo (MC) calculation has fully replaced conventional measurements, which are time-consuming and have limited sensitivity to clinically relevant errors. A fully automated and robust pipeline was developed, integrating two clinical workflows based on the fast MC code Fred. The system is fully operational, and automatic verification reports are part of daily clinical practice. The first workflow performs a pre-treatment dose recalculation in Fred using the planning CT and clinical plan. The second uses Fred with machine log files to verify the actually delivered dose. Both generate automatic reports for clinical review. Over five years, this workflow has become part of routine clinical operations, providing robust 3D dosimetric verification in heterogeneous anatomies. So far, Fred has recalculated more than 6000 pre-treatment plans and 3513 log file-based PSQA cases, saving an estimated 4090 hours of QA work. The pipeline identified true negatives and detected two planning-related failures that would have been missed by conventional measurements. No false positives or negatives were observed, confirming high accuracy and reliability. The MC-based PSQA pipeline offers an efficient, sensitive, and clinically meaningful alternative to measurement-based QA in pencil beam scanning proton therapy. By eliminating routine measurements, it saves resources while improving patient safety and treatment quality. Five years of experience confirm that measurement-less MC-based PSQA is a viable and superior approach, providing full 3D verification and early error detection - a practical blueprint for other proton therapy centres.
- 11 January 2025
- Published by Elsevier in Physica Medica
- Vol. 130, 104890
Proton therapy of lung cancer patients – Treatment strategies and clinical experience from a medical physicist’s perspective
- 11 January 2025
- Published by Elsevier in Physica Medica
- Vol. 130, 104890
Proton therapy of lung cancer patients – Treatment strategies and clinical experience from a medical physicist’s perspective
- Open Access
- 26 July 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1149) , 20230110
Clinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients
Objective: Several studies have shown that dual-energy CT (DECT) can lead to improved accuracy for proton range estimation. This study investigated the clinical benefit of reduced range uncertainty, enabled by DECT, in robust optimisation for neuro-oncological patients. Methods: DECT scans for 27 neuro-oncological patients were included. Commercial software was applied to create stopping-power ratio (SPR) maps based on the DECT scan. Two plans were robustly optimised on the SPR map, keeping the beam and plan settings identical to the clinical plan. One plan was robustly optimised and evaluated with a range uncertainty of 3% (as used clinically; denoted 3%-plan); the second plan applied a range uncertainty of 2% (2%-plan). Both plans were clinical acceptable and optimal. The dose–volume histogram parameters were compared between the two plans. Two experienced neuro-radiation oncologists determined the relevant dose difference for each organ-at-risk (OAR). Moreover, the OAR toxicity levels were assessed. Results: For 24 patients, a dose reduction >0.5/1 Gy (relevant dose difference depending on the OAR) was seen in one or more OARs for the 2%-plan; e.g. for brainstem D0.03cc in 10 patients, and hippocampus D40% in 6 patients. Furthermore, 12 patients had a reduction in toxicity level for one or two OARs, showing a clear benefit for the patient. Conclusion: Robust optimisation with reduced range uncertainty allows for reduction of OAR toxicity, providing a rationale for clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. Advances in knowledge: This study shows the clinical benefit of range uncertainty reduction from 3% to 2% in robustly optimised proton plans. A dose reduction to one or more OARs was seen for 89% of the patients, and 44% of the patients had an expected toxicity level decrease.
- 26 July 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1149) , 20230110
Open AccessClinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients
Objective: Several studies have shown that dual-energy CT (DECT) can lead to improved accuracy for proton range estimation. This study investigated the clinical benefit of reduced range uncertainty, enabled by DECT, in robust optimisation for neuro-oncological patients. Methods: DECT scans for 27 neuro-oncological patients were included. Commercial software was applied to create stopping-power ratio (SPR) maps based on the DECT scan. Two plans were robustly optimised on the SPR map, keeping the beam and plan settings identical to the clinical plan. One plan was robustly optimised and evaluated with a range uncertainty of 3% (as used clinically; denoted 3%-plan); the second plan applied a range uncertainty of 2% (2%-plan). Both plans were clinical acceptable and optimal. The dose–volume histogram parameters were compared between the two plans. Two experienced neuro-radiation oncologists determined the relevant dose difference for each organ-at-risk (OAR). Moreover, the OAR toxicity levels were assessed. Results: For 24 patients, a dose reduction >0.5/1 Gy (relevant dose difference depending on the OAR) was seen in one or more OARs for the 2%-plan; e.g. for brainstem D0.03cc in 10 patients, and hippocampus D40% in 6 patients. Furthermore, 12 patients had a reduction in toxicity level for one or two OARs, showing a clear benefit for the patient. Conclusion: Robust optimisation with reduced range uncertainty allows for reduction of OAR toxicity, providing a rationale for clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. Advances in knowledge: This study shows the clinical benefit of range uncertainty reduction from 3% to 2% in robustly optimised proton plans. A dose reduction to one or more OARs was seen for 89% of the patients, and 44% of the patients had an expected toxicity level decrease.
- Open Access
- 23 December 2020
- Published by Frontiers Media SA in Frontiers in Physics
- Vol. 8
Implementation of a Compact Spot-Scanning Proton Therapy System in a GPU Monte Carlo Code to Support Clinical Routine
The purpose of this work was to implement a fast Monte Carlo dose calculation tool, Fred, in the Maastro proton therapy center in Maastricht (Netherlands) to complement the clinical treatment planning system. Fred achieves high accuracy and computation speed by using physics models optimized for radiotherapy and extensive use of GPU technology for parallelization. We implemented the beam model of the Mevion S250i proton beam and validated it against data measured during commissioning and calculated with the clinical TPS. The beam exits the accelerator with a pristine energy of around 230 MeV and then travels through the dynamically extendable nozzle of the device. The nozzle contains the range modulation system and the multi-leaf collimator system named adaptive aperture. The latter trims the spots laterally over the 20 × 20 cm2 area at the isocenter plane. We use a single model to parameterize the longitudinal (energy and energy spread) and transverse (beam shape) phase space of the non-degraded beam in the default nozzle position. The range modulation plates and the adaptive aperture are simulated explicitly and moved in and out of the simulation geometry dynamically by Fred. Patient dose distributions recalculated with Fred were comparable with the TPS and met the clinical criteria. Calculation time was on the order of 10–15 min for typical patient cases, and future optimization of the simulation statistics is likely to improve this further. Already now, Fred is fast enough to be used as a tool for plan verification based on machine log files and daily (on-the-fly) dose recalculations in our facility.
- 23 December 2020
- Published by Frontiers Media SA in Frontiers in Physics
- Vol. 8
Open AccessImplementation of a Compact Spot-Scanning Proton Therapy System in a GPU Monte Carlo Code to Support Clinical Routine
The purpose of this work was to implement a fast Monte Carlo dose calculation tool, Fred, in the Maastro proton therapy center in Maastricht (Netherlands) to complement the clinical treatment planning system. Fred achieves high accuracy and computation speed by using physics models optimized for radiotherapy and extensive use of GPU technology for parallelization. We implemented the beam model of the Mevion S250i proton beam and validated it against data measured during commissioning and calculated with the clinical TPS. The beam exits the accelerator with a pristine energy of around 230 MeV and then travels through the dynamically extendable nozzle of the device. The nozzle contains the range modulation system and the multi-leaf collimator system named adaptive aperture. The latter trims the spots laterally over the 20 × 20 cm2 area at the isocenter plane. We use a single model to parameterize the longitudinal (energy and energy spread) and transverse (beam shape) phase space of the non-degraded beam in the default nozzle position. The range modulation plates and the adaptive aperture are simulated explicitly and moved in and out of the simulation geometry dynamically by Fred. Patient dose distributions recalculated with Fred were comparable with the TPS and met the clinical criteria. Calculation time was on the order of 10–15 min for typical patient cases, and future optimization of the simulation statistics is likely to improve this further. Already now, Fred is fast enough to be used as a tool for plan verification based on machine log files and daily (on-the-fly) dose recalculations in our facility.
- 13 December 2019
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1107) , 20190598
Beam commissioning of the first compact proton therapy system with spot scanning and dynamic field collimation
Objectives: To describe the measurements and to present the results of the beam commissioning and the beam model validation of a compact, gantry-mounted, spot scanning proton accelerator system with dynamic layer-by-layer field collimation. Methods: We performed measurements of depth dose distributions in water, spot and scanned field size in air at different positions from the isocenter plane, spot position over the 20 × 20 cm2 scanned area, beam monitor calibration in terms of absorbed dose to water and specific field collimation measurements at different gantry angles to commission the system. To validate the beam model in the treatment planning system (TPS), we measured spot profiles in water at different depths, absolute dose in water of single energy layers of different field sizes and inversely optimised spread-out Bragg peaks (SOBP) under normal and oblique beam incidence, field size and penumbra in water of SOBPs, and patient treatment specific quality assurance in homogeneous and heterogeneous phantoms. Results: Energy range, spot size, spot position and dose output were consistent at all gantry angles with 0.3 mm, 0.4 mm, 0.6 mm and 0.5% maximum deviations, respectively. Uncollimated spot size (one sigma) in air with an air-gap of 10 cm ranged from 4.1 to 16.4 mm covering a range from 32.2 to 1.9 cm in water, respectively. Absolute dose measurements were within 3% when comparing TPS and experimental data. Gamma pass rates >98% and >96% at 3%/3 mm were obtained when performing 2D dose measurements in homogeneous and in heterogeneous media, respectively. Leaf position was within ±1 mm at all gantry angles and nozzle positions. Conclusions: Beam characterisation and machine commissioning results, and the exhaustive end-to-end tests performed to assess the proper functionality of the system, confirm that it is safe and accurate to treat patients. Advances in knowledge: This is the first paper addressing the beam commissioning and the beam validation of a compact, gantry-mounted, pencil beam scanning proton accelerator system with dynamic layer-by-layer multileaf collimation.
- 13 December 2019
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 93 (1107) , 20190598
Beam commissioning of the first compact proton therapy system with spot scanning and dynamic field collimation
Objectives: To describe the measurements and to present the results of the beam commissioning and the beam model validation of a compact, gantry-mounted, spot scanning proton accelerator system with dynamic layer-by-layer field collimation. Methods: We performed measurements of depth dose distributions in water, spot and scanned field size in air at different positions from the isocenter plane, spot position over the 20 × 20 cm2 scanned area, beam monitor calibration in terms of absorbed dose to water and specific field collimation measurements at different gantry angles to commission the system. To validate the beam model in the treatment planning system (TPS), we measured spot profiles in water at different depths, absolute dose in water of single energy layers of different field sizes and inversely optimised spread-out Bragg peaks (SOBP) under normal and oblique beam incidence, field size and penumbra in water of SOBPs, and patient treatment specific quality assurance in homogeneous and heterogeneous phantoms. Results: Energy range, spot size, spot position and dose output were consistent at all gantry angles with 0.3 mm, 0.4 mm, 0.6 mm and 0.5% maximum deviations, respectively. Uncollimated spot size (one sigma) in air with an air-gap of 10 cm ranged from 4.1 to 16.4 mm covering a range from 32.2 to 1.9 cm in water, respectively. Absolute dose measurements were within 3% when comparing TPS and experimental data. Gamma pass rates >98% and >96% at 3%/3 mm were obtained when performing 2D dose measurements in homogeneous and in heterogeneous media, respectively. Leaf position was within ±1 mm at all gantry angles and nozzle positions. Conclusions: Beam characterisation and machine commissioning results, and the exhaustive end-to-end tests performed to assess the proper functionality of the system, confirm that it is safe and accurate to treat patients. Advances in knowledge: This is the first paper addressing the beam commissioning and the beam validation of a compact, gantry-mounted, pencil beam scanning proton accelerator system with dynamic layer-by-layer multileaf collimation.